SCHEMBL7204770

SCHEMBL7204770

CNC(=O)C1=Cc2c(ccc3ccc(OC)cc23)OC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 6/20 0.50
SHMT2 P34897 1/20 0.49
MAPT P10636 2/20 0.46
GAA P10253 2/20 0.46
MEN1 O00255 1/20 0.46
HSP90AA1 P07900 1/20 0.46
HTT P42858 1/20 0.46
KMT2A Q03164 1/20 0.46
PTGS1 P23219 1/20 0.45
PTGS2 P35354 1/20 0.45
NPC1 O15118 1/20 0.44
NFKB1 P19838 1/20 0.44
RAB9A P51151 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TP53 P04637 1/20 0.43
ALOX5 P09917 2/20 0.43
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7199599 0.86 PTGS1 (0.47) MTNR1ASHMT2MAPTGAAMEN1
SCHEMBL6075764 0.84 NR1H4 (0.41) MTNR1ASHMT2MAPTGAAMEN1
SCHEMBL19313390 0.76 HNF4A (0.50) MTNR1ASHMT2MAPTGAAMEN1
SCHEMBL5226489 0.73 PTGS1 (0.41) MTNR1ASHMT2MAPTGAAMEN1
SCHEMBL30955901 0.68 SHMT2 (0.54) MTNR1ASHMT2MAPTGAAMEN1
SCHEMBL30955900 0.68 SHMT2 (0.54) MTNR1ASHMT2MAPTGAAMEN1
SCHEMBL2014811 0.68 LMNA (0.47) SHMT2MAPTHTTALOX5KDM4E
SCHEMBL31613073 0.67 MTNR1A (1.00) MTNR1AGAAKDM4EALDH1A1GLA
SCHEMBL9058391 0.66 MAOB (0.64) MTNR1ASHMT2MAPTGAAMEN1
SCHEMBL3198679 0.66 MAOB (0.64) MTNR1ASHMT2MAPTGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6602903-B2 Substituted O- and/or S heterocyclic compounds; powerful ligands for melatoninergic receptors. LES LABORATORIES SERVIER (FR) 2003-08-05 US disclosed
US-20020052400-A1 Substituted heterocyclic compounds ADIR ET COMPAGNIE 2002-05-02 US disclosed
US-6313160-B1 FOR THERAPY AND PROPHYLAXIS OF MELATONINERGIC DISORDERS ADIR ET COMPAGNIE (FR) 2001-11-06 US disclosed
EP-0998471-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING AND COMPOSITIONS CONTAINING SAME ADIR ET COMPAGNIE (FR) 2000-05-10 EP disclosed
WO-1998052935-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING AND COMPOSITIONS CONTAINING SAME ADIR ET COMPAGNIE (FR) 1998-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052400-A1 Substituted heterocyclic compounds MTNR1A, MTNR1B, CBR1 MTNR1A 1/4885SHMT2 449/4885MAPT 3970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.